A successful second allogeneic hematopoietic stem cell transplantation from an alternative donor in a patient with loss of HLA heterozygosity relapse of juvenile myelomonocytic leukemia: case series analysis
Authors:
- L. A. TsvetkovaLTL. A. Tsvetkova
- A. A. OsipovaAOA. A. Osipova
- A. V. EvdokimovAEA. V. Evdokimov
- P. V. KozhokarPKP. V. Kozhokar
- Zh. Z. RakhmanovaZRZh. Z. Rakhmanova
- I. M. BarkhatovIBI. M. Barkhatov
- O. V. PainaOPO. V. Paina
- O. S. EpifanovskayaOEO. S. Epifanovskaya
- E. V. BabenkoEBE. V. Babenko
- N. E. IvanovaNIN. E. Ivanova
- D. V. KozlovDKD. V. Kozlov
- T. L. GindinaTGT. L. Gindina
Open Access
- 30 September 2023
- journal article
- research article
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (3) , 28-35
Abstract
Juvenile myelomonocytic leukemia (JMML) is a rare and aggressive myeloproliferative/myelodysplastic neoplasm of early childhood characterized by activation of the Ras signaling pathway. Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only proven curative treatment for JMML. However, the 5-year overall survival is about 52–64%. In this work, we analyzed 4 clinical cases of patients with relapses of JMML with loss of heterozygosity in HLA (LoH) after allo-HSCT. The patients' parents gave their consent to the use of their children's data, including photographs, for research purposes and in publications. Two patients received a second allo-HSCT from an alternative donor, two patients – from the same donor. A positive result in the form of a durable remission was observed in one patient who underwent a second allo-HSCT from an alternative donor and restored HLA genetic heterozygosity. At the same time, immunotherapy with infusions of donor lymphocytes led to the development of graft-versus-host disease without potentiating the antileukemic effect. Thus, a second allo-HSCT from an alternative donor for the treatment of relapsed JMML with HLA LoH is necessary to restore the “graft-versus-JMML” response. The study was approved by the Independent Ethics Committee and the Scientific Council of the I.P. Pavlov First Saint Petersburg State Medical University of Ministry of Healthcare of the Russian Federation.Keywords
This publication has 22 references indexed in Scilit:
- Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndromeBone Marrow Transplantation, 2019
- Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia – a matched pair analysis by the Acute Leukaemia Working Party of EBMTBritish Journal of Haematology, 2018
- A new tool for rapid and reliable diagnosis of HLA loss relapses after HSCTBlood, 2017
- Loss of Mismatched HLA on the Leukemic Blasts of Patients With Relapsed Lymphoid Malignancies Following Bone Marrow Transplantation From Related Donors With HLA Class II Mismatches in the Graft Versus Host DirectionPediatric Blood & Cancer, 2015
- Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantationLeukemia, 2014
- Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR studyBlood, 2013
- Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemiaLeukemia, 2005
- Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trialBlood, 2005
- Second Allogeneic Hematopoietic Stem Cell Transplantation for Juvenile Myelomonocytic Leukemia: Case Report and Literature ReviewJournal of Pediatric Hematology/Oncology, 2004
- Successful treatment of juvenile myelomonocytic leukemia relapsing after stem cell transplantation using donor lymphocyte infusionBlood, 2003